MENU
+Compare
VRNA
Stock ticker: NASDAQ
AS OF
Apr 24, 04:59 PM (EDT)
Price
$64.85
Change
+$1.54 (+2.43%)
Capitalization
5.38B

VRNA Verona Pharma plc Forecast, Technical & Fundamental Analysis

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs... Show more

VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for VRNA with price predictions
Apr 23, 2025

VRNA's RSI Indicator recovers from oversold territory

The RSI Oscillator for VRNA moved out of oversold territory on April 07, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 25 similar instances when the indicator left oversold territory. In of the 25 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on April 17, 2025. You may want to consider a long position or call options on VRNA as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for VRNA just turned positive on April 17, 2025. Looking at past instances where VRNA's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

VRNA moved above its 50-day moving average on April 23, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VRNA advanced for three days, in of 287 cases, the price rose further within the following month. The odds of a continued upward trend are .

VRNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The 10-day moving average for VRNA crossed bearishly below the 50-day moving average on April 04, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for VRNA entered a downward trend on April 16, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (26.316) is normal, around the industry mean (14.056). P/E Ratio (0.000) is within average values for comparable stocks, (63.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.788). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (121.951) is also within normal values, averaging (252.992).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

VRNA is expected to report earnings to rise 33.40% to -6 cents per share on April 29

Verona Pharma plc VRNA Stock Earnings Reports
Q1'25
Est.
$-0.07
Q4'24
Beat
by $0.02
Q3'24
Est.
$-0.07
Q2'24
Missed
by $0.06
Q1'24
Missed
by $0.01
The last earnings report on February 27 showed earnings per share of -5 cents, beating the estimate of -7 cents. With 877.22K shares outstanding, the current market capitalization sits at 5.38B.
A.I. Advisor
published General Information

General Information

a r&d company for the treatment of allergic rhinitis and other chronic respiratory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
3 More London Riverside
Phone
+44 2032834200
Employees
79
Web
https://www.veronapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PGRO33.830.83
+2.50%
Putnam Focused Large Cap Growth ETF
TDIV70.381.60
+2.33%
First Trust NASDAQ Technology Div ETF
BFEB40.250.47
+1.17%
Innovator U.S. Equity Buffer ETF™ - Feb
BLE9.800.08
+0.82%
BlackRock Municipal Income Trust II
ULE12.43-0.29
-2.28%
ProShares Ultra Euro

VRNA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VRNA has been loosely correlated with VCYT. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if VRNA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRNA
1D Price
Change %
VRNA100%
+2.10%
VCYT - VRNA
38%
Loosely correlated
+1.08%
COGT - VRNA
38%
Loosely correlated
+3.00%
CRNX - VRNA
37%
Loosely correlated
+3.55%
CLDX - VRNA
36%
Loosely correlated
+0.23%
TRDA - VRNA
36%
Loosely correlated
N/A
More